Abstract
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | BMJ. British Medical Journal (International Ed.) |
| Vol/bind | 338 |
| Sider (fra-til) | b249 |
| ISSN | 0959-8146 |
| Status | Udgivet - 2009 |
Bibliografisk note
Keywords: Adolescent; Adult; Age of Onset; Aged; Cohort Studies; Denmark; Female; Fertility Agents; Humans; Infertility, Female; Maternal Age; Middle Aged; Ovarian Neoplasms; Parity; Pregnancy; Risk Factors; Young AdultCitationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
I: BMJ. British Medical Journal (International Ed.), Bind 338, 2009, s. b249.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
}
TY - JOUR
T1 - Use of fertility drugs and risk of ovarian cancer: Danish Population Based Cohort Study
AU - Jensen, Allan
AU - Sharif, Heidi
AU - Frederiksen, Kirsten
AU - Kjaer, Susanne Krüger
N1 - Keywords: Adolescent; Adult; Age of Onset; Aged; Cohort Studies; Denmark; Female; Fertility Agents; Humans; Infertility, Female; Maternal Age; Middle Aged; Ovarian Neoplasms; Parity; Pregnancy; Risk Factors; Young Adult
PY - 2009
Y1 - 2009
N2 - OBJECTIVE: To examine the effects of fertility drugs on overall risk of ovarian cancer using data from a large cohort of infertile women. DESIGN: Population based cohort study. SETTING: Danish hospitals and private fertility clinics. PARTICIPANTS: 54,362 women with infertility problems referred to all Danish fertility clinics during 1963-98. The median age at first evaluation of infertility was 30 years (range 16-55 years), and the median age at the end of follow-up was 47 (range 18-81) years. Included in the analysis were 156 women with invasive epithelial ovarian cancer (cases) and 1241 subcohort members identified in the cohort during follow-up in 2006. MAIN OUTCOME MEASURE: Effect of four groups of fertility drugs (gonadotrophins, clomifene citrate, human chorionic gonadotrophin, and gonadotrophin releasing hormone) on overall risk of ovarian cancer after adjustment for potential confounding factors. RESULTS: Analyses within cohort showed no overall increased risk of ovarian cancer after any use of gonadotrophins (rate ratio 0.83, 95% confidence interval 0.50 to 1.37), clomifene (1.14, 0.79 to 1.64), human chorionic gonadotrophin (0.89, 0.62 to 1.29), or gonadotrophin releasing hormone (0.80, 0.42 to 1.51). Furthermore, no associations were found between all four groups of fertility drugs and number of cycles of use, length of follow-up, or parity. CONCLUSION: No convincing association was found between use of fertility drugs and risk of ovarian cancer.
AB - OBJECTIVE: To examine the effects of fertility drugs on overall risk of ovarian cancer using data from a large cohort of infertile women. DESIGN: Population based cohort study. SETTING: Danish hospitals and private fertility clinics. PARTICIPANTS: 54,362 women with infertility problems referred to all Danish fertility clinics during 1963-98. The median age at first evaluation of infertility was 30 years (range 16-55 years), and the median age at the end of follow-up was 47 (range 18-81) years. Included in the analysis were 156 women with invasive epithelial ovarian cancer (cases) and 1241 subcohort members identified in the cohort during follow-up in 2006. MAIN OUTCOME MEASURE: Effect of four groups of fertility drugs (gonadotrophins, clomifene citrate, human chorionic gonadotrophin, and gonadotrophin releasing hormone) on overall risk of ovarian cancer after adjustment for potential confounding factors. RESULTS: Analyses within cohort showed no overall increased risk of ovarian cancer after any use of gonadotrophins (rate ratio 0.83, 95% confidence interval 0.50 to 1.37), clomifene (1.14, 0.79 to 1.64), human chorionic gonadotrophin (0.89, 0.62 to 1.29), or gonadotrophin releasing hormone (0.80, 0.42 to 1.51). Furthermore, no associations were found between all four groups of fertility drugs and number of cycles of use, length of follow-up, or parity. CONCLUSION: No convincing association was found between use of fertility drugs and risk of ovarian cancer.
M3 - Journal article
C2 - 19196744
SN - 0959-8146
VL - 338
SP - b249
JO - BMJ. British Medical Journal (International Ed.)
JF - BMJ. British Medical Journal (International Ed.)
ER -